2016 annual financial data

CRISPR Therapeutics 2016 Financial results

Direct answer

Revenue was 5,164,000 USD.

Operating income was -68,130,000 USD and net income was -23,202,000 USD.
Operating cash flow was -55,310,000 USD.

Get free CRISPR Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
5,164,000 USD
Operating income
-68,130,000 USD
Net income
-23,202,000 USD
Operating cash flow
-55,310,000 USD